The Conversation (0)
December 22, 2025
INN Article Notification
02 December 2025
Invion Secures Expanded Photosoft Global Exclusive License
Invion Limited (IVX:AU) has announced Invion Secures Expanded Photosoft Global Exclusive LicenseDownload the PDF here. Keep Reading...
30 October 2025
Appendix 4C and Quarterly Activities Report - September 2025
Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
20 October 2025
Funded Collaboration Agreement with Protect Animal Health
Invion Limited (IVX:AU) has announced Funded Collaboration Agreement with Protect Animal HealthDownload the PDF here. Keep Reading...
09 October 2025
Repayment of Lind Facility with Successful Capital Raise
Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...
07 October 2025
Trading Halt
Invion Limited (IVX:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
7h
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT at ASCO 2026
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breast cancer (MBC) patientsBiomarker analyses from the ongoing Phase 3 study confirm predictors of... Keep Reading...
19 May
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
KELOWNA, BC / ACCESS Newswire / May 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an independent review board, for Human Pilot Study #7... Keep Reading...
15 May
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+
BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor... Keep Reading...
14 May
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer
Bria-PROS+ is BriaCell's next generation personalized off-the-shelf immunotherapy for prostate cancerImmune stimulating components of Bria-PROS+ enhance anti-tumor responsesBriaCell has completed manufacturing clinical supplies of Bria-PROS+ and plans to initiate a Phase 1/2a clinical study in... Keep Reading...
13 May
BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell"... Keep Reading...
12 May
Hantavirus Outbreak Sparks Rollercoaster Ride for Biotech Stocks
A localized hantavirus outbreak aboard an Atlantic cruise ship triggered a brief, speculative frenzy in biotechnology stocks this week.Shares of prominent vaccine developers fluctuated on Monday (May 11) as retail investors attempted to front run what they perceived as a burgeoning global health... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00